| LOSS PER SHARE |
7. LOSS PER SHARE
Basic and diluted net loss per common share were
the same since the inclusion of common shares issuable pursuant to the exercise of options in the calculation of diluted net loss per
common shares would have been antidilutive.
For the years ended December 31, 2025 and 2024,
loss per share of the Company are as follows:
SCHEDULE OF LOSS PER SHARE
| | |
For the Year Ended | | |
For the Year Ended | |
| | |
December 31, | | |
December 31, | |
| | |
2025 | | |
2024 | |
| Numerator: | |
| | | |
| | |
| Net Loss | |
$ | (1,756,096 | ) | |
$ | (1,505,102 | ) |
| Net loss attributable to common shareholders | |
$ | (1,756,096 | ) | |
$ | (1,505,102 | ) |
| Denominator: | |
| | | |
| | |
| Weighted-average common shares outstanding, basic and diluted | |
| 15,233,501 | | |
| 11,435,362 | |
| | |
| | | |
| | |
| Net loss per common share, basic and diluted | |
$ | (0.12 | ) | |
$ | (0.13 | ) |
The Company’s potentially dilutive securities,
which include stock options and warrants, have been excluded from the computation of diluted net loss per common share as the effect would
be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic
and diluted net loss per share attributable to common shareholders is the same.
The Company excluded the following from the computation
of diluted net loss per share attributable to common stockholders for the years ended December 31, 2025 and 2024 because including them
would have had an anti-dilutive effect:
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
| | |
For the Year Ended | | |
For the Year Ended | |
| | |
December 31, | | |
December 31, | |
| | |
2025 | | |
2024 | |
| Stock options to purchase common stock outstanding | |
| 1,759,211 | | |
| 1,445,211 | |
| Warrants to purchase common stock outstanding | |
| 350,000 | | |
| 350,000 | |
| Total | |
| 2,109,211 | | |
| 1,795,211 | |
| Anti-dilutive shares | |
| 2,109,211 | | |
| 1,795,211 | |
|